@inproceedings{inproceedings, title  = {{DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation}},

 url = {{}},

 year = {{2020}},

 month = {{1}},

 author = {{Sengupta S and Niazi T and Williams S and Davis ID and Stockler M and Martin AJ and Bracken K and Roncolato FT and McJannett M and Horvath L and Hughes S et al}},

 volume = {{16}},

 journal = {{ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY}},

 pages = {{204-204}},

 note = {{Accessed on 2024/10/23}}}